Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
-Medical News
 Blood Safety News
 NHF and Community News
 Industry News
 Travel Advisory

 

 

 
NIAID Awards Wyeth Contract to Develop HIV Vaccine
 

Wyeth Pharmaceuticals has been awarded a five-year, $32 million contract from the National Institute of Allergy and Infectious Disease (NIAID) to develop therapeutic HIV vaccines. Wyeth will develop the vaccines in conjunction with researchers at the University of Pennsylvania, Duke University in North Carolina and the Beth Israel/Deaconess Hospital in Boston, MA. The award is part of NIAID's HIV Vaccine Design and Development Teams (HVDDT) program. NIAID is an agency of the National Institutes of Health (NIH).

“The Wyeth HIV vaccine program is focused on the identification and clinical evaluation of vaccine approaches capable of eliciting robust and sustained anti-HIV immunological responses,” said Emilio A. Emini, PhD, executive vice president for Wyeth Vaccines Research & Development. “We look forward to continuing our work with the NIH on a program that has been a very gratifying scientific partnership.”

Previous NIAID/Wyeth contracts through the HVDDT program have led to the development and manufacturing of HIV vaccine prototypes. These prototypes are currently in Phase I clinical studies.

Source: Wyeth news release dated December 1, 2005

 

This section of our Web site is sponsored by: